Authorised KMPs to determine materiality of events/information
Cadila Healthcare Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".15-12-2015
15-12-2015
Mankind Pharma launches anti-diabetic product Dynaglipt
Zydus Cadila also launches its generic Tenglyn tablets, Gliptins, in the Indian market for Rs 7 per tablet Mankind Pharma has launched an anti-diabetic product Dynaglipt targeting the middle class and rural diabetic patients. The company has launched anti-diabetic product for the diabetic patients targeting the middle class and rural diabetic patients, so as to []24-11-2015
Drug launch to keep Cadila Health in focus
Zydus Cadila has launched tablet Tenglyn, the generic version of oral anti-diabetic drug Gliptins, in India. Tenglyn, priced at 7 a tablet, is almost a sixth of the price at which Gliptins was in...21-11-2015
Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 20, 2015 titled "Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India".20-11-2015
Zydus to start phase-II clinical trials for Saroglitazar in US
Cadila Healthcare (Zydus Cadila) today announced the US drug regulator has endorsed company's plan to initiate a phase 2 clinical trial of Saroglitazar18-11-2015
Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 18, 2015 titled "Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA".18-11-2015
Cadila heads for pharma's top 5
Cadila Healthcare's stock gained 2.6% to hit a new high of Rs 454.40 on Friday, before closing at its highest till date of Rs 442.8528-10-2015
Cadila posts 41% jump in net profit to Rs 391 cr
Healthcare player, Zydus Cadila (Cadila Healthcare), on Thursday reported consolidated net profit of Rs 391 crore for the second quarter ended September 2015, up by 41 per cent from Rs 278 crore r...22-10-2015
Announces Q2 results, Results Press Release & Limited Review Report for the Quarter ended September 30, 2015
Cadila Healthcare Ltd has announced the following results for the quarter ended September 30, 2015:The Unaudited Standalone results for the Quarter ended September 30, 2015The Company has posted a net profit of Rs. 6140.80 million for the quarter ended September 30, 2015 as compared to Rs. 3656.10 million for the quarter ended September 30, 2014. Total Income has increased from Rs. 13966.00 million for the quarter ended September...22-10-2015
Updates on Result of Postal Ballot
Cadila Healthcare Ltd has submitted to BSE a copy of Minutes of announcement of result of Postal ballot / e-voting by the Company on September 22, 2015.15-10-2015